Adaptive CFO sells 2,145 shares under 10b5-1 plan

Adaptive Biotechnologies Chief Financial Officer Kyle Piskel reported routine share transactions under a pre-set trading plan.

Rhea-AI Filing Summary

Adaptive Biotechnologies Chief Financial Officer Kyle Piskel reported routine share transactions under a pre-set trading plan. On February 4, 2026, he exercised 2,145 stock options at $12.14 per share and acquired the same number of common shares.

That same day, he sold 2,145 common shares at $18.46 per share under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following these transactions, he directly owned 216,637 shares of common stock and 2,146 stock options. The options originally vested 25% on March 4, 2023, with the remainder vesting monthly thereafter.

Insider Trade Summary

Exercise and Sale: 2,145 shares ($14K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider PISKEL KYLE

Role Chief Financial Officer

Sold 2,145 shs ($40K)

Approx. gross sale proceeds $40K

Approx. exercise cost $26K

Approx. pre-tax spread $14K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	2,145	$0.00	$0.00
Exercise	Common Stock	2,145	$12.14	$26K
Sale	Common Stock	2,145	$18.46	$40K

Holdings After Transaction: Stock Option (right to buy) — 2,146 contracts (Direct); Common Stock — 216,637 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.
2. F2. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADPT CFO Kyle Piskel report on this Form 4?

Kyle Piskel reported exercising options and selling shares of Adaptive Biotechnologies (ADPT). On February 4, 2026, he exercised 2,145 stock options and sold 2,145 common shares, all under a pre-arranged Rule 10b5-1 trading plan.

How many Adaptive Biotechnologies (ADPT) shares did the CFO sell and at what price?

The CFO sold 2,145 common shares of Adaptive Biotechnologies at $18.46 per share on February 4, 2026. These sales followed the exercise of 2,145 options at $12.14 per share on the same date.

What is the size and price of the ADPT stock options exercised by the CFO?

He exercised 2,145 stock options with an exercise price of $12.14 per share. The options relate to common stock of Adaptive Biotechnologies and were partly exercised on February 4, 2026 as disclosed in the Form 4 filing.

How many Adaptive Biotechnologies (ADPT) shares does the CFO own after these transactions?

After the reported transactions, the CFO directly owns 216,637 shares of common stock in Adaptive Biotechnologies. He also holds 2,146 stock options following the 2,145-option exercise reported for February 4, 2026.

Were the ADPT CFO’s trades made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan. This plan was adopted by the reporting person on August 28, 2025, allowing pre-scheduled trades that continue regardless of later material nonpublic information.

What is the vesting schedule of the ADPT stock options exercised by the CFO?

The options vested 25% on March 4, 2023, with 1/48 of the shares vesting at the end of each full month of continuous service thereafter. This monthly vesting continued until the option grant became fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 07:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PISKEL KYLE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		M(1)		2,145	A	$12.14	218,782	D
Common Stock	02/04/2026		S(1)		2,145	D	$18.46	216,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$12.14	02/04/2026		M(1)			2,145	(2)	03/04/2032	Common Stock	2,145	$0	2,146	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

2. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Kyle Piskel	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.